Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6941766 | 0.82 | MEN1 (0.54) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6940041 | 0.80 | MEN1 (0.54) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6946378 | 0.79 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6944295 | 0.78 | MEN1 (0.58) | MEN1KMT2APPARGALDH1A1MAPT | |
| SCHEMBL6943714 | 0.78 | HPGD (0.46) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6940835 | 0.77 | ALDH1A1 (0.69) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6939542 | 0.77 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6941580 | 0.77 | HPGD (0.54) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4693343 | 0.77 | SMN1; SMN2 (0.66) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6942084 | 0.76 | MMP13 (0.57) | MEN1KMT2APPARGALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | MEN1 2660/4885KMT2A 1991/4885PPARG 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.